Investing

Scholar Rock : SRRK

SRRK

Stock Data

$46.37

$0.24 (0.51%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Scholar Rock Holding Corp is a pioneering biopharmaceutical firm based in Cambridge, Massachusetts, dedicated to crafting innovative medicines for severe diseases where protein growth factor signaling is key. Its leading product, Apitegromab, targets spinal muscular atrophy and has reached Phase 3 clinical trials. Additionally, the company is exploring SRK-181 for certain cancer treatments resistant to existing therapies and is developing treatments for neuromuscular disorders, cancer, fibrosis, and anemia. Scholar Rock collaborates with Gilead Sciences to tackle fibrotic diseases, showcasing its commitment to addressing complex medical challenges.

All Scholar Rock Articles

2 Articles

Trey Thoelcke | Oct 17, 2025 at 8:45 AM EDT

Insiders Bet Big on These 3 Fintech and Biotech Stocks

In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were…

Omor Ibne Ehsan | Oct 8, 2025 at 2:34 PM EDT

Wall Street Insiders Are Loading Up on These 3 Stocks

People don’t like to throw money into a sinking ship, and by that logic, insider buys in Wall Street can…